OTCPK:NUGS

Stock Analysis Report

Executive Summary

Cannabis Strategic Ventures distributes Nano products in the Western Hemisphere.


Snowflake Analysis

Imperfect balance sheet with weak fundamentals.

Share Price & News

How has Cannabis Strategic Ventures's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NUGS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

47.4%

NUGS

-2.3%

US Pharmaceuticals

-2.7%

US Market


1 Year Return

-94.8%

NUGS

14.1%

US Pharmaceuticals

21.2%

US Market

Return vs Industry: NUGS underperformed the US Pharmaceuticals industry which returned 12.6% over the past year.

Return vs Market: NUGS underperformed the US Market which returned 24.7% over the past year.


Shareholder returns

NUGSIndustryMarket
7 Day47.4%-2.3%-2.7%
30 Day147.7%0.4%0.09%
90 Day6.5%10.7%6.9%
1 Year-94.8%-94.8%17.0%14.1%23.8%21.2%
3 Year71.9%71.9%38.7%28.8%48.1%38.6%
5 Yearn/a29.2%15.6%72.5%53.4%

Price Volatility Vs. Market

How volatile is Cannabis Strategic Ventures's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cannabis Strategic Ventures undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Cannabis Strategic Ventures is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Cannabis Strategic Ventures has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of NUGS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Cannabis Strategic Ventures regulatory filings here.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Cannabis Strategic Ventures forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

21.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cannabis Strategic Ventures has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Cannabis Strategic Ventures performed over the past 5 years?

8.5%

Historical Pharmaceuticals & Biotech annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Cannabis Strategic Ventures has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Cannabis Strategic Ventures's financial position?


In this section we usually analyse Cannabis Strategic Ventures's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Cannabis Strategic Ventures has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of NUGS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Cannabis Strategic Ventures's financial data was last updated here.
  • Explore more healthy companies in the Pharmaceuticals & Biotech industry.

Dividend

What is Cannabis Strategic Ventures's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.7%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate NUGS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate NUGS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NUGS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NUGS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NUGS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Cannabis Strategic Ventures's salary, the management and board of directors tenure and is there insider trading?

0.3yrs

Average board tenure


CEO

Simon Yu 0

0yrs

Tenure

0

Mr. Simon Yu has been Chief Executive Officer of Cannabis Strategic Ventures and served as its Director until September 2019. He served as Chief Operations Officer at SugarMade, Inc. from February 03, 2017 ...


Board Age and Tenure

0.3yrs

Average Tenure

Experienced Board: NUGS's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Management Team

  • J. Brown

    Secretary and Director

    • Paul Hutchin

      President

      • Tenure: 4.3yrs
    • Simon Yu

      Chief Executive Officer

      • Alan Tran

        Head of Finance

        • Chris Young

          Chief Strategy Officer & Director

          • John Vu

            Legal Counsel

            • Arlene Guzman

              Vice President of Operations


              Board Members

              • Pyng Soon (59yo)

                Independent Director

                • Tenure: 0.3yrs
              • Chris Young

                Chief Strategy Officer & Director

                • George Wen

                  Chairman

                  • Tenure: 0.3yrs
                • Danny Cheung

                  Independent Director

                  • Tenure: 0.3yrs
                • Yang Lin

                  Independent Director

                  • Tenure: 0.3yrs

                Company Information

                Cannabis Strategic Ventures's company bio, employee growth, exchange listings and data sources


                Key Information

                • Name: Cannabis Strategic Ventures
                • Ticker: NUGS
                • Exchange: OTCPK
                • Founded: 2014
                • Industry: Pharmaceuticals
                • Sector: Pharmaceuticals & Biotech
                • Market Cap: US$22.183m
                • Shares outstanding: 268.88m
                • Website: https://www.cannabisstrategic.com

                Location

                • Cannabis Strategic Ventures
                • 2724 Otter Creek Court
                • Suite 101
                • Las Vegas
                • Nevada
                • 89117-1732
                • United States

                Listings

                TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
                NUGSOTCPK (Pink Sheets LLC)YesCommon StockUSUSDFeb 2005

                Biography

                Cannabis Strategic Ventures distributes Nano products in the Western Hemisphere. It offers Nano Sand Shield that binds with oil, arsenic, and gold. The company’s products are used in environmental, tailings management, and water decontamination applications in disaster response, oil and gas, mining, pipeline, rail, and truck transportation sectors. It provides its products through representative agents in the United States and Canada. The company was incorporated in 2014 and is based in Las Vegas, Nevada with an additional office in Vancouver, Canada. 


                Company Analysis and Financial Data Status

                All financial data provided by Standard & Poor's Capital IQ.
                DataLast Updated (UTC time)
                Company Analysis2020/01/29 00:06
                End of Day Share Price2020/01/28 00:00
                EarningsN/A
                Annual EarningsN/A


                Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.